Adding trilaciclib to pre-surgery chemotherapy for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new drug called trilaciclib, which is added to standard chemotherapy given before breast cancer surgery. The goal is to see if it helps shrink the tumor and possibly reduces side effects like low blood cell counts, making the treatment easier to tolerate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have been diagnosed with invasive triple-negative breast cancer that has not been treated before (you have not had chemotherapy, surgery, or other cancer treatment)
- Your cancer is at a stage where it can be removed with surgery, and you are planning to have chemotherapy before surgery to shrink it
- You are generally in good health (able to do light activities) and your heart, liver, and kidneys are working well
- If you are able to become pregnant, you must agree to use effective contraception during the study and for 7 months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding trilaciclib to standard chemotherapy after surgery can help people with hormone receptor-negative breast cancer. It aims to reduce side effects and improve treatment outcomes.
This trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow and improve treatment for advanced triple-negative breast cancer. It may reduce side effects and help you tolerate treatment better.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This study tests a new drug (a CDK inhibitor) given before your regular chemotherapy for triple-negative breast cancer. The goal is to understand how the drug affects the tumor, which might help guide future treatments.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
Hear when a new Breast Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.